Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) saw an upside of 10.36% to $17.90 after adding $1.68 on Wednesday. The 5-day average trading volume is 498,968 shares of the company’s common stock. It has gained $18.37 in the past week and touched a new high 5 times within the past 5 days. An average of 737,857 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 730,257.
ICPT’s 1-month performance is 20.77% or $6.26 on its low of $11.44 reached on 12/27/22. The company’s shares have touched a 52-week low of $10.81 and high of $21.25, with the stock’s rally to the 52-week high happening on 01/25/23. YTD, ICPT has achieved 31.12% or $5.72 and has reached a new high 9 times. However, the current price is down -15.76% from the 52-week high price.
ICPT stock has a beta of 1.20. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.14 while the price-to-book (PB) in the most recent quarter is 5.17.
Intercept Pharmaceuticals Inc.’s quick ratio for the period ended September 29 was 2.50, with the current ratio over the same period at 2.50. As well, the company’s long term debt to equity for the quarter ending September 29 was 2.07, while the total debt to equity was 3.09. In terms of profitability, the gross margin trailing 12 months is 99.30%. The firm’s gross profit as reported stood at $360.37 million against revenue of $363.47 million.
For the quarterly period ending September 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 101.36% to $267.45 million, while revenue of -$7.53 million was 102.82% off the previous quarter. Analysts expected ICPT to announce $4.61 per share in earnings in its latest quarter, but it posted $7.8, representing a 69.20% surprise. EBITDA for the quarter stood at more than -$9.67 million. ICPT stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 451.73 million, with total debt at $339.6 million. Shareholders hold equity totaling $41.42 million.
Let’s look briefly at Intercept Pharmaceuticals Inc. (ICPT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 76.21% to suggest the stock is trending Overbought, with historical volatility in this time period at 73.37%.
The stock’s 5-day moving average is $16.35, reflecting a +15.00% or $2.36 change from its current price. ICPT is currently trading +52.92% above its 20-day SMA, +4.15% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +13.42% and SMA200 by+2.84%.
Stochastic %K and %D was 88.57% and 85.38% and the average true range (ATR) pointed at 1.01. The RSI (14) points at 70.04%, while the 14-day stochastic is at 95.16% with the period’s ATR at 0.97. The stock’s 9-day MACD Oscillator is pointing at 0.48 and 1.07 on the 14-day charts.
In the most recent analyst report for Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), B. Riley Securities upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for ICPT stock have a consensus rating for the stock as Hold. Currently, 1 brokerage advisors rate ICPT as a “sell,”, while 9 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 2 rates the stock as overweight while 3 have offered a “buy” rating.
What is ICPT’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $11.00 and a high of $49.00, with their median price target at $21.00. Looking at these predictions, the average price target given by analysts is for Intercept Pharmaceuticals Inc. (ICPT) stock is $22.50.